| Year |
Citation |
Score |
| 2022 |
Zeleke TZ, Pan Q, Chiuzan C, Onishi M, Li Y, Tan H, Alvarez MJ, Honan E, Yang M, Chia PL, Mukhopadhyay P, Kelly S, Wu R, Fenn K, Trivedi MS, ... ... Yu J, et al. Network-based assessment of HDAC6 activity predicts preclinical and clinical responses to the HDAC6 inhibitor ricolinostat in breast cancer. Nature Cancer. PMID 36585452 DOI: 10.1038/s43018-022-00489-5 |
0.555 |
|
| 2022 |
Roussel MF, Jonchere B, Williams J, Zindy F, Liu J, Robinson S, Farmer DM, Min J, Yang L, Stripay JL, Wang Y, Freeman BB, Yu J, Shelat AA, Rankovic Z. Combination of ribociclib with BET-bromodomain and PI3K/mTOR inhibitors for medulloblastoma treatment in vitro and in vivo. Molecular Cancer Therapeutics. PMID 36318650 DOI: 10.1158/1535-7163.MCT-21-0896 |
0.318 |
|
| 2022 |
Zhao X, Wang P, Diedrich JD, Smart B, Reyes N, Yoshimura S, Zhang J, Yang W, Barnett K, Xu B, Li Z, Huang X, Yu J, Crews K, Yeoh AEJ, et al. Epigenetic activation of the FLT3 gene by ZNF384 fusion confers a therapeutic susceptibility in acute lymphoblastic leukemia. Nature Communications. 13: 5401. PMID 36104354 DOI: 10.1038/s41467-022-33143-w |
0.343 |
|
| 2022 |
Chaudhary KR, Kinslow CJ, Cheng H, Silva JM, Yu J, Wang TJ, Hei TK, Halmos B, Cheng SK. Smurf2 inhibition enhances chemotherapy and radiation sensitivity in non-small-cell lung cancer. Scientific Reports. 12: 10140. PMID 35710591 DOI: 10.1038/s41598-022-14448-8 |
0.308 |
|
| 2020 |
Autry RJ, Paugh SW, Carter R, Shi L, Liu J, Ferguson DC, Lau CE, Bonten EJ, Yang W, McCorkle JR, Beard JA, Panetta JC, Diedrich JD, Crews KR, Pei D, ... ... Yu J, et al. Integrative genomic analyses reveal mechanisms of glucocorticoid resistance in acute lymphoblastic leukemia. Nature Cancer. 1: 329-344. PMID 32885175 DOI: 10.1038/S43018-020-0037-3 |
0.391 |
|
| 2020 |
Tosello V, Bongiovanni D, Liu J, Pan Q, Yan KK, Saccomani V, Van Trimpont M, Pizzi M, Mazzoni M, Dei Tos AP, Amadori A, Zanovello P, Van Vlierberghe P, Yu J, Piovan E. Cross-talk between GLI transcription factors and FOXC1 promotes T-cell acute lymphoblastic leukemia dissemination. Leukemia. PMID 32733009 DOI: 10.1038/S41375-020-0999-2 |
0.39 |
|
| 2020 |
Hao Shi, Yan KK, Ding L, Qian C, Chi H, Yu J. Network Approaches for Dissecting the Immune System. Iscience. 23: 101354. PMID 32717640 DOI: 10.1016/J.Isci.2020.101354 |
0.312 |
|
| 2020 |
Marks DK, Gartrell RD, El Asmar M, Boboila S, Hart T, Lu Y, Pan Q, Yu J, Hibshoosh H, Guo H, Andreopoulou E, Wiechmann L, Crew K, Sparano J, Hershman D, et al. Akt Inhibition Is Associated With Favorable Immune Profile Changes Within the Tumor Microenvironment of Hormone Receptor Positive, HER2 Negative Breast Cancer. Frontiers in Oncology. 10: 968. PMID 32612958 DOI: 10.3389/Fonc.2020.00968 |
0.37 |
|
| 2020 |
Wijaya J, Vo BT, Liu J, Xu B, Wu G, Wang Y, Peng J, Zhang J, Janke LJ, Orr BA, Yu J, Roussel MF, Schuetz JD. An ABC transporter drives medulloblastoma pathogenesis by regulating Sonic Hedgehog signaling. Cancer Research. PMID 31948942 DOI: 10.1158/0008-5472.Can-19-2054 |
0.389 |
|
| 2020 |
Silva J, Kalinsky K, Chiuzan C, Zeleke T, Qingfei P, Yu J. Abstract CT107: Phase IB trial of ACY-1215 (ricolinostat) combined with nab-paclitaxel in metastatic breast cancer (MBC) Cancer Research. 80. DOI: 10.1158/1538-7445.Am2020-Ct107 |
0.434 |
|
| 2019 |
Yu J, Peng J, Chi H. Systems immunology: Integrating multi-omics data to infer regulatory networks and hidden drivers of immunity. Current Opinion in Systems Biology. 15: 19-29. PMID 32789283 DOI: 10.1016/J.Coisb.2019.03.003 |
0.315 |
|
| 2019 |
Wei J, Long L, Zheng W, Dhungana Y, Lim SA, Guy C, Wang Y, Wang YD, Qian C, Xu B, Kc A, Saravia J, Huang H, Yu J, Doench JG, et al. Targeting REGNASE-1 programs long-lived effector T cells for cancer therapy. Nature. PMID 31827283 DOI: 10.1038/S41586-019-1821-Z |
0.398 |
|
| 2019 |
Mamcarz E, Zhou S, Lockey T, Boi S, Koon-Kiu Y, Cross S, Kang G, Ma Z, Condori JM, Dowdy J, Metais J, Langfitt D, Triplett B, Li C, Zhao X, ... ... Yu J, et al. Lentiviral Gene Therapy with Low Dose Busulfan for Infants with X-SCID Results in the Development of a Functional Normal Immune System: Interim Results of an Ongoing Phase I/II Clinical Study Blood. 134: 2058-2058. DOI: 10.1182/Blood-2019-126746 |
0.314 |
|
| 2019 |
Shaw TI, Dong L, High A, Liu Y, Ju B, Kavdia K, Pagala V, Shaner B, Easton J, Qian C, Yu J, Janke J, Choi JK, Peng J, Gu W, et al. Abstract 3652: USP7 heterozygous loss-of-function affects T-cell differentiation in pediatric T-ALL Cancer Research. 79: 3652-3652. DOI: 10.1158/1538-7445.Am2019-3652 |
0.353 |
|
| 2018 |
Khatamian A, Paull EO, Califano A, Yu J. SJARACNe: a scalable software tool for gene network reverse engineering from big data. Bioinformatics (Oxford, England). PMID 30388204 DOI: 10.1093/Bioinformatics/Bty907 |
0.496 |
|
| 2018 |
Boboila S, Lopez G, Yu J, Banerjee D, Kadenhe-Chiweshe A, Connolly EP, Kandel JJ, Rajbhandari P, Silva JM, Califano A, Yamashiro DJ. Transcription factor activating protein 4 is synthetically lethal and a master regulator of MYCN-amplified neuroblastoma. Oncogene. PMID 29880876 DOI: 10.1038/S41388-018-0326-9 |
0.593 |
|
| 2018 |
Du X, Wen J, Wang Y, Karmaus PWF, Khatamian A, Tan H, Li Y, Guy C, Nguyen TM, Dhungana Y, Neale G, Peng J, Yu J, Chi H. Hippo/Mst signalling couples metabolic state and immune function of CD8α dendritic cells. Nature. PMID 29849151 DOI: 10.1038/S41586-018-0177-0 |
0.347 |
|
| 2018 |
Yu J, Silva JM. Bayesian Network to Infer Drug-Induced Apoptosis Circuits from Connectivity Map Data. Methods in Molecular Biology (Clifton, N.J.). 1783: 361-378. PMID 29767372 DOI: 10.1007/978-1-4939-7834-2_18 |
0.391 |
|
| 2018 |
Rajbhandari P, Lopez G, Capdevila C, Salvatori B, Yu J, Rodriguez-Barrueco R, Martinez D, Yarmarkovich M, Weichert-Leahey N, Abraham BJ, Alvarez MJ, Iyer A, Harenza JL, Oldridge D, De Preter K, et al. Cross-cohort analysis identifies a TEAD4 ↔ MYCN positive-feedback loop as the core regulatory element of high-risk neuroblastoma. Cancer Discovery. PMID 29510988 DOI: 10.1158/2159-8290.Cd-16-0861 |
0.549 |
|
| 2018 |
Kalinsky K, Onishi M, Yu J, Trivedi MS, Accordino MK, Crew KD, Hershman DL, Maurer MA, Silva J. Phase IB trial of ACY-1215 (Ricolinostat) combined with nab-paclitaxel in metastatic breast cancer. Journal of Clinical Oncology. 36: 1058-1058. DOI: 10.1200/Jco.2018.36.15_Suppl.1058 |
0.34 |
|
| 2018 |
Zeleke TZ, Putcha P, Yu J, Califano A, Silva JM. Abstract 2898: Inhibition of HDAC6 as a novel targeted therapy in breast cancer Cancer Research. 78: 2898-2898. DOI: 10.1158/1538-7445.Am2018-2898 |
0.624 |
|
| 2017 |
Putcha P, Yu J, Rodriguez-Barrueco R, Saucedo-Cuevas L, Villagrasa P, Murga-Penas E, Quayle SN, Yang M, Castro V, Llobet-Navas D, Birnbaum D, Finetti P, Woodward WA, Bertucci F, Alpaugh ML, et al. Erratum to: HDAC6 activity is a non-oncogene addiction hub for inflammatory breast cancers. Breast Cancer Research : Bcr. 19: 49. PMID 28424080 DOI: 10.1186/S13058-017-0841-6 |
0.557 |
|
| 2017 |
Rodriguez-Barrueco R, Nekritz EA, Bertucci F, Yu J, Sanchez-Garcia F, Zeleke TZ, Gorbatenko A, Birnbaum D, Ezhkova E, Cordon-Cardo C, Finetti P, Llobet-Navas D, Silva JM. miR-424(322)/503 is a breast cancer tumor suppressor whose loss promotes resistance to chemotherapy. Genes & Development. 31: 553-566. PMID 28404630 DOI: 10.1101/Gad.292318.116 |
0.378 |
|
| 2017 |
Yu J, Silva JM, Califano A. Abstract PR10: ScreenBEAM: a Novel Meta-Analysis Algorithm for Functional Genomics Screens via Bayesian Hierarchical Modeling Molecular Cancer Therapeutics. 16. DOI: 10.1158/1538-8514.Synthleth-Pr10 |
0.554 |
|
| 2016 |
Tosello V, Saccomani V, Yu J, Bordin F, Amadori A, Piovan E. Calcineurin complex isolated from T-cell acute lymphoblastic leukemia (T-ALL) cells identifies new signaling pathways including mTOR/AKT/S6K whose inhibition synergize with Calcineurin inhibition to promote T-ALL cell death. Oncotarget. PMID 27304189 DOI: 10.18632/Oncotarget.9933 |
0.396 |
|
| 2016 |
Yu J, Califano A, silva j. Abstract B36: Inhibition of the autocrine IL-6-JAK2-STAT3-Calprotectin axis as targeted therapy for HR-/HER2+ breast cancers Molecular Cancer Research. 14. DOI: 10.1158/1557-3125.Advbc15-B36 |
0.628 |
|
| 2016 |
Putcha P, Yu J, Rodriguez-Barrueco R, Califano A, silva j. Abstract A71: HDAC6 activity is a non-oncogene addiction hub for in inflammatory breast cancers Molecular Cancer Research. 14. DOI: 10.1158/1557-3125.Advbc15-A71 |
0.636 |
|
| 2016 |
Rajbhandari P, Lopez G, Yu J, Rodriguez-Barrueco R, Alvarez M, Martinez D, Yarmarkovich M, Vandesompele J, Mestdagh P, Silva JM, Lasorella A, Iavarone A, Maris JM, Califano A. Abstract 4384: Selective cross-cohort discovery of transcriptional mechanisms presiding over high-risk neuroblastoma subtype state maintenance Cancer Research. 76: 4384-4384. DOI: 10.1158/1538-7445.Am2016-4384 |
0.601 |
|
| 2015 |
Cheng H, Zhang Z, Rodriguez-Barrueco R, Borczuk A, Liu H, Yu J, Silva JM, Cheng SK, Perez-Soler R, Halmos B. Functional genomics screen identifies YAP1 as a key determinant to enhance treatment sensitivity in lung cancer cells. Oncotarget. PMID 26716514 DOI: 10.18632/Oncotarget.6721 |
0.397 |
|
| 2015 |
Tosello V, Bordin F, Yu J, Agnusdei V, Indraccolo S, Basso G, Amadori A, Piovan E. Calcineurin and GSK-3 inhibition sensitizes T-cell acute lymphoblastic leukemia cells to apoptosis through X-linked inhibitor of apoptosis protein (XIAP) degradation. Leukemia. PMID 26648536 DOI: 10.1038/Leu.2015.335 |
0.363 |
|
| 2015 |
Putcha P, Yu J, Rodriguez-Barrueco R, Saucedo-Cuevas L, Villagrasa P, Murga-Penas E, Quayle SN, Yang M, Castro V, Llobet-Navas D, Birnbaum D, Finetti P, Woodward WA, Bertucci F, Alpaugh ML, et al. HDAC6 activity is a non-oncogene addiction hub for inflammatory breast cancers. Breast Cancer Research : Bcr. 17: 149. PMID 26643555 DOI: 10.1186/S13058-015-0658-0 |
0.645 |
|
| 2015 |
Yu J, Silva J, Califano A. ScreenBEAM: a Novel Meta-Analysis Algorithm for Functional Genomics Screens via Bayesian Hierarchical Modeling. Bioinformatics (Oxford, England). PMID 26415723 DOI: 10.1093/Bioinformatics/Btv556 |
0.543 |
|
| 2015 |
O'Brien SK, Chen L, Zhong W, Armellino D, Yu J, Loreth C, Follettie M, Damelin M. Breast cancer cells respond differentially to modulation of TGF-β2 signaling after exposure to chemotherapy or hypoxia. Cancer Research. PMID 26340918 DOI: 10.1158/0008-5472.Can-15-0650 |
0.435 |
|
| 2015 |
Rodriguez-Barrueco R, Yu J, Saucedo-Cuevas LP, Olivan M, Llobet-Navas D, Putcha P, Castro V, Murga-Penas EM, Collazo-Lorduy A, Castillo-Martin M, Alvarez M, Cordon-Cardo C, Kalinsky K, Maurer M, Califano A, et al. Inhibition of the autocrine IL-6-JAK2-STAT3-calprotectin axis as targeted therapy for HR-/HER2+ breast cancers. Genes & Development. 29: 1631-48. PMID 26227964 DOI: 10.1101/Gad.262642.115 |
0.618 |
|
| 2015 |
Yu J, Putcha P, Silva JM. Recovering drug-induced apoptosis subnetwork from Connectivity Map data. Biomed Research International. 2015: 708563. PMID 25883971 DOI: 10.1155/2015/708563 |
0.407 |
|
| 2015 |
Sato M, Rodriguez-Barrueco R, Yu J, Do C, Silva JM, Gautier J. MYC is a critical target of FBXW7. Oncotarget. 6: 3292-305. PMID 25669969 DOI: 10.18632/Oncotarget.3203 |
0.471 |
|
| 2015 |
Zhang S, Lopez G, Yu J, Silva J, Kadenhe-Chiweshe A, Califano A, Yamashiro D. Abstract 2083: TFAP4 inhibits differentiation of MYCN-amplified neuroblastoma Cancer Research. 75: 2083-2083. DOI: 10.1158/1538-7445.Am2015-2083 |
0.574 |
|
| 2014 |
Putcha P, Yu J, Califano A, Silva J. Abstract 4623: HDAC6 inhibition is a novel strategy to selectively impact inflammatory breast cancer cell survival Cancer Research. 74: 4623-4623. DOI: 10.1158/1538-7445.Am2014-4623 |
0.627 |
|
| 2014 |
Barrueco RR, Yu J, Alvarez M, Castro V, Marshall N, Su R, Castro L, Maurer M, Califano A, Silva JM. Abstract 2761: Characterizing the mechanism and the clinical relevance of the synthetic lethal interaction between STAT3 inhibition and HER2 overexpression in breast cancers Cancer Research. 74: 2761-2761. DOI: 10.1158/1538-7445.Am2014-2761 |
0.652 |
|
| 2013 |
Piovan E, Yu J, Tosello V, Herranz D, Ambesi-Impiombato A, Da Silva AC, Sanchez-Martin M, Perez-Garcia A, Rigo I, Castillo M, Indraccolo S, Cross JR, de Stanchina E, Paietta E, Racevskis J, et al. Direct reversal of glucocorticoid resistance by AKT inhibition in acute lymphoblastic leukemia. Cancer Cell. 24: 766-76. PMID 24291004 DOI: 10.1016/J.Ccr.2013.10.022 |
0.539 |
|
| 2013 |
Yu J, Putcha P, Califano A, Silva JM. Pooled shRNA screenings: computational analysis. Methods in Molecular Biology (Clifton, N.J.). 980: 371-84. PMID 23359167 DOI: 10.1007/978-1-62703-287-2_22 |
0.516 |
|
| 2013 |
Cheng H, Zhang Z, Rodriguez-Barrueco R, Yu J, Silva JM, Cheng S, Perez-Soler R, Halmos B. Abstract 2044: Down-regulation of YAP sensitizes lung cancer cells to platinum and ionizing radiation. Cancer Research. 73: 2044-2044. DOI: 10.1158/1538-7445.Am2013-2044 |
0.46 |
|
| 2013 |
Rodriguez-Barrueco R, Yu J, Alvarez M, Castro V, Villagrasa P, Marshall N, Sun R, Castro L, Califano A. Abstract PR11: Characterizing the mechanism and the clinical relevance of the synthetic lethal interaction between STAT3 inhibition and HER2 overexpression in breast cancers Molecular Cancer Therapeutics. 12. DOI: 10.1158/1535-7163.Pms-Pr11 |
0.657 |
|
| 2013 |
Yu J, Gao Y, Zhong W, Chen L, Apanovitch D, Follettie M, Rejto P, Arndt K. Abstract A33: Optimizing NGS-based shRNA screening experiments and data analysis Molecular Cancer Therapeutics. 12. DOI: 10.1158/1535-7163.Pms-A33 |
0.399 |
|
| 2012 |
Yu J, Piovan E, Flaherty MS, Silva J, Ferrando A, Califano A. Abstract A35: Discovery of driver-type therapeutic targets to reverse glucocorticoid resistance in T-ALL Cancer Research. 72. DOI: 10.1158/1538-7445.Csb12-A35 |
0.575 |
|
| 2010 |
Piovan E, Yu J, Real P, Ann GM, Califano A, Ferrando A. Oncogenic AKT Signaling Negatively Regulates Glucocorticoid Receptor Function to Promote Glucocorticoid Resistance In T Cell Acute Lymphoblastic Leukemia Blood. 116: 11-11. DOI: 10.1182/Blood.V116.21.11.11 |
0.573 |
|
| 2009 |
Lü B, Yu J, Xu J, Chen J, Lai M. A novel approach to detect differentially expressed genes from count-based digital databases by normalizing with housekeeping genes. Genomics. 94: 211-6. PMID 19446020 DOI: 10.1016/J.Ygeno.2009.05.003 |
0.388 |
|
| 2008 |
Lü B, Xu J, Chen J, Yu J, Xu E, Lai M. TaqMan low density array is roughly right for gene expression quantification in colorectal cancer. Clinica Chimica Acta; International Journal of Clinical Chemistry. 389: 146-51. PMID 18179774 DOI: 10.1016/J.Cca.2007.12.009 |
0.361 |
|
| Show low-probability matches. |